ArticleAmerican journal of translational research2024
Efficacy of butylphthalein injection combined with alteplase thrombolysis in patients with acute cerebral infarction and its impact on Lp-PLA2 and CXCL16 levels.
Article in American journal of translational research, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveTo evaluate the efficacy of butylphthalein injection combined with alteplase thrombolysis in patients with acute cerebral infarction (ACI) and its effects on lipoprotein-associated phospholipase A2 (Lp-PLA2) and CXC chemokine ligand 16 (CXCL16) levels.
methodsA total of 127 ACI patients admitted to Shandong Provincial Third Hospital between March 2020 and June 2023 were included and divided into a butylphthalein group (n = 67) and a control group (n = 60) based on their treatment regimen. All patients received basic treatment. Additionally, the control group underwent intravenous thrombolysis with alteplase, while the butylphthalein group received butylphthalein injection combined with alteplase thrombolysis. Both groups were treated for two consecutive weeks.
resultsThe overall clinical efficacy rate in the butylphthalein group was significantly higher than that in the control group (P < 0.05). After treatment, cerebral infarction size and National Institutes of Health Stroke Scale (NIHSS) scores were significantly reduced in both groups (both P < 0.05), with greater reductions observed in the butylphthalein group (both P < 0.05). The peak systolic velocity (Vs) of the posterior cerebral, vertebral, and basilar arteries increased significantly in both groups after treatment compared with baseline (all P < 0.05), with higher values in the butylphthalein group (all P < 0.05). The resistance index (RI) of these arteries decreased significantly in both groups after treatment (P < 0.05) and was lower in the butylphthalein group than in the control group (P < 0.05). Serum levels of IL-6, TNF-α, CRP, Lp-PLA2, and CXCL16 were significantly lower after treatment in both groups (all P < 0.05), with greater reductions in the butylphthalein group (all P < 0.05). There was no significant difference in adverse effects between the two groups (P > 0.05).
conclusionThe combination of butylphthalein injection and alteplase intravenous thrombolysis is effective in improving clinical outcomes, reducing neurological deficits, enhancing microcirculation, and lowering serum Lp-PLA2 and CXCL16 levels in patients with ACI. This therapy is worth clinical promotion.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.